Nicotinamide Mononucleotide (NMN)
SupplementThe small divergence of −4 points indicates that medical evidence [s2, s7, s8] and community perception [c1, c2, c3] are similarly assessed: both recognize a moderate but not compelling benefit. The medical evidence is somewhat more strongly supported by measurable biomarkers (NAD+, insulin sensitivity), while a portion of the community reports no subjective effects [c1, c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
NMN demonstrably raises NAD⁺ levels in humans and shows early RCT evidence for improvements in muscle insulin sensitivity and physical performance — more than most longevity supplements can claim. However, study populations are small, durations short (mostly 8–12 weeks), and a convincing anti-aging proof of concept in healthy humans is still missing. In Germany, NMN has no approved status as a food supplement and sits in a clear legal grey zone. Those who use it anyway should prioritise verified quality brands and keep expectations realistic.
Description
NMN is an NAD+ precursor molecule that raises NAD+ levels in human studies and shows initial evidence for improvements in insulin sensitivity, muscle strength, and lipid profile [s1, s2, s3].
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide found in small amounts in foods such as broccoli, edamame, and avocado [s4]. In the body, it serves as a direct precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for hundreds of enzymatic reactions, energy metabolism, DNA repair, and cell survival [s4, s5]. With advancing age, tissue NAD+ levels decline significantly, which is considered a hallmark of the aging process [s5]. NMN supplementation aims to compensate for this age-related NAD+ decline. In mice, NMN has been shown to be absorbed within 10 minutes via the Slc12a8 transporter in the small intestine and converted to NAD+ [s4]. However, the precise uptake mechanism in humans remains an active area of research [s5]. Completed human studies have demonstrated that oral NMN intake reliably increases blood NAD+ levels [s1, s6, s7]. Initial clinical evidence suggests improvements in muscle insulin sensitivity in prediabetic women [s7], physical performance [s2], and lipid profiles and body weight [s1]. However, the evidence base predominantly consists of small RCTs with short study durations, and clinically relevant anti-aging proof in humans has yet to be established [s8, s9]. Within the EU, NMN is in a regulatory grey area: no Novel Food authorization has been granted, and initial EFSA assessments are ongoing [s13, s14]. Products are nonetheless available online and widely discussed in the biohacking community.
Legal Status (DE)
In Germany and the EU, the legal status of NMN is unresolved. As of April 2026, no EU-wide Novel Food authorization exists; several applications are pending with EFSA [s13]. The German consumer protection organization (Verbraucherzentrale Deutschland) notes that under German and European law, NMN may be classified as a chemical not approved for human consumption [s12]. In the United States, the FDA revised its earlier decision in September 2025, confirming NMN as a legal dietary supplement under DSHEA [s14]. Suppliers in Germany therefore operate in a legal grey area.
Mechanism of Action
NMN raises intracellular NAD+ levels via the salvage biosynthesis pathway [s5]. Following absorption, NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferase (NMNAT) [s4, s5]. Within the Preiss-Handler and de novo synthesis pathways, intermediates such as nicotinic acid mononucleotide (NAMN) and nicotinic acid adenine dinucleotide (NAAD) are formed, which also lead to NAD+ [s5]. NAD+ activates sirtuins (SIRT1–SIRT7), a family of NAD+-dependent deacetylases that regulate cell repair, mitochondrial function, and metabolic homeostasis [s4, s5]. Additionally, PARP enzymes (involved in DNA repair) and CD38 (an NAD+-hydrolyzing enzyme) are modulated by NAD+ [s5]. In muscle cells specifically, NMN has been shown to enhance insulin signaling pathways (PI3K/Akt pathway) and increase muscular glucose uptake [s7]. Elevation of NAD+ by NMN also leads to improved mitochondrial biogenesis and blood oxygen transport capacity [s9]. A mechanistic debate continues regarding whether NMN must first be degraded to nicotinamide riboside (NR) before cellular uptake can occur, or whether direct transport via Slc12a8 is possible [s4, s10].
Dosing
NAD+-Erhöhung / allgemeines Longevity-Protokoll
- Dose
- 250–500 mg NMN daily
- Frequency
- 1× täglich morgens
- Route
- oral
- Duration
- fortlaufend (Langzeitsicherheit >12 Monate nicht belegt)
- Timing
- Morning fasted or with breakfast
- With food
- optional
Muskel-Insulinsensitivität (prädiabetische Frauen)
- Dose
- 250 mg NMN daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 10 Wochen
- Timing
- Morning after breakfast
- With food
- empfohlen
Physische Leistungsfähigkeit
- Dose
- 250–500 mg NMN daily
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 8–12 Wochen
- Timing
- Morning
- With food
- optional
Höhere Dosierung (Sicherheitsstudie)
- Dose
- 900 mg NMN daily
- Frequency
- aufgeteilt auf 3 Dosen
- Route
- oral
- Duration
- Bis 4 Wochen (klinische Studien)
- Timing
- Split with meals
- With food
- empfohlen
In safety studies, single doses up to 500 mg [s6] and daily doses up to 900 mg [s11] were tolerated without serious adverse effects. No official upper limit has been established by BfR or EFSA for NMN, as no EU authorization exists [s12, s13]. Long-term safety beyond 12 months has not been established.
Sublingual administration is marketed by some manufacturers as more bioavailable (2–3× faster absorption); clinical evidence for this is very limited and based on pilot data [s15]. Standard capsules/powder are the most thoroughly studied dosage forms. NMN should not be stored at elevated temperatures, as it can degrade to nicotinamide [s16].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Magenbeschwerden, Durchfall) Mild GI complaints were occasionally reported in human studies with up to 500 mg/day. Of 437 study participants, 8.2% reported minor adverse effects, a portion of which were GI-related [s11]. | gelegentlich | leicht |
| Kopfschmerzen Reported sporadically in clinical studies; no consistent signal across studies [s11]. | selten | leicht |
| Schwindel oder Müdigkeit Individual reports from clinical studies and user reports; causality unclear [s11, s16]. | selten | leicht |
| Hautausschlag / Urtikaria Mentioned as a possible adverse effect in individual clinical reports; causal relationship not established [s11]. | selten | leicht |
| Muskelschmerzen nach Absetzen (Rebound-Effekt) Described sporadically by Reddit users; no documented clinical evidence; possible nocebo reaction or correlation with training changes [c1]. | theoretisch | moderat |
| Potenzielle Tumorpromotion (theoretisch) Animal studies with NR (not NMN) in aggressive cancer models showed possible promotion of tumor proliferation; no human evidence for NMN. Experts recommend caution in known malignancies [s11]. | theoretisch | schwer |
Contraindications
Theoretically, elevated NAD+ levels could promote tumor growth, as cancer cells require NAD+ for replication. No direct human evidence for NMN, but caution is recommended by experts [s11].
No safety data available for pregnant or breastfeeding women. Use not recommended until relevant studies are available [s16].
No safety or efficacy data available for individuals under 18 years. Use not recommended [s11].
Possible interactions due to NAD+ modulation of cellular processes specifically targeted by chemotherapeutic agents; no clinical data available [s11].
Interactions
Synergistic
Resveratrol activates SIRT1 (NAD⁺-dependent deacetylase); combination with NMN could synergistically enhance sirtuin activity. To date supported only mechanistically/in animal studies, no human trials [s4].
Metformin influences AMPK and mitochondrial function similarly to NAD⁺ elevation; combined effects are discussed in longevity research. No completed RCTs [s5].
Apigenin inhibits the enzyme CD38, which degrades NAD⁺. In combination with NMN, this simultaneously increases NAD⁺ production and reduces its degradation, potentially resulting in sustainably higher NAD⁺ levels.
Fisetin is frequently combined with NMN in longevity protocols, as both compounds may support cellular health via complementary mechanisms (sirtuin activation, senolysis). Evidence is predominantly preclinical and mechanistic to date.
NMN increases NAD⁺ for mitochondrial energy production, while CoQ10 supports electron transport in the respiratory chain. Current evidence suggests the combination may synergistically improve mitochondrial function.
Berberine activates AMPK – similarly to metformin – and thus acts via related metabolic pathways to NMN. A combination could potentiate metabolic and mitochondrial effects, though no controlled human studies are available to date.
High NMN doses increase methylation demand, as nicotinamide (NAM), a degradation product of NAD⁺, must be methylated. TMG provides methyl groups and may thereby counteract a rise in homocysteine levels.
Methylfolate supports the methylation cycle and can – similarly to TMG – help compensate for the increased methylation demand with intensive NMN supplementation. Particularly relevant in individuals with MTHFR gene variants.
Quercetin acts as a CD38 modulator and can inhibit NAD⁺ degradation similarly to apigenin. In combination with NMN, this could lead to a more sustained increase in NAD⁺ levels; evidence is predominantly preclinical to date.
Caution
NMN increases NAD⁺, which is a substrate for PARP enzymes (DNA repair). Concomitant use with PARP inhibitors could affect their efficacy; no human studies [s11].
One RCT reported significant reduction in diastolic blood pressure with NMN [s1]; additive hypotension possible with concurrent antihypertensive therapy. Close blood pressure monitoring recommended.
NMN improves insulin sensitivity [s7]; additive hypoglycemia risks possible with concurrent antidiabetic medication.
Studies
Tier A — High Evidence
Outcome: Safety profile and pharmacodynamics of NMN in humans
Effect Size: No adverse events; dose-dependent increase in NMN metabolites in blood over 5 hours
Outcome: NAD+ levels, LDL cholesterol, body weight, diastolic blood pressure
Effect Size: Significant reduction in total LDL, non-HDL cholesterol, body weight, and diastolic blood pressure
Outcome: Muscle insulin sensitivity (hyperinsulinemic euglycemic clamp)
Effect Size: Significant improvement in insulin sensitivity in muscle tissue (p<0.05); improved insulin signaling (PI3K/Akt pathway)
Tier B — Moderate Evidence
Outcome: Safety and anti-aging effects of NMN in human studies
Effect Size: NMN increases NAD+ concentration and may attenuate age-related disorders such as oxidative stress, DNA damage, and inflammatory responses; evidence still insufficient for clinical recommendation
Outcome: Glucose and lipid metabolism, NAD+ levels, muscle performance
Effect Size: Consistent NAD+ elevation; indications of improvements in insulin resistance, lipid profile, and muscle health in middle-aged and older adults
Outcome: Physical performance parameters under NMN supplementation
Effect Size: NMN improves physical performance parameters; well tolerated without serious adverse effects
Tier C — Low Evidence
Outcome: Multifunctional properties and mechanisms of action of NMN
Effect Size: Summary of biosynthetic pathways, pharmacodynamic effects, and clinical trial results; no independent effect size calculated
Community Evidence
Top reported benefits
- Increased energy and reduced fatigue in daily life
- Improved athletic recovery and regeneration
- Perceived improvement in cognitive clarity
- Better sleep quality (reported in isolated cases)
- Increased general vitality in older users
Top reported issues
- No noticeable effects in a significant proportion of users
- High cost relative to uncertain efficacy
- Muscle pain and fatigue upon discontinuation (isolated reports)
- Legal grey area in Germany causes confusion among users
- Quality variability between suppliers
A relevant proportion of users report no subjectively perceptible effect [c1, c4]. The absence of EU authorization and the associated legal uncertainty are perceived as problematic in German-language forums [c5]. The community actively debates quality differences between brands (e.g., Uthever as a pharmaceutical-grade brand [c2]) and whether NMN must first be degraded to NR before cellular uptake can occur [c4].
Scientific Sources
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Yi L, Maier AB, Tao R, et al. (2023). GeroScienceAPMID:36482258DOI - Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation
Trammell SAJ, Schmidt MS, Weidemann BJ, et al. (2025). Science AdvancesBDOI - NMN Side Effects, Safety Profile, and Drug Interactions: What the Clinical Research Shows in 2026
UT Cardiothoracic Surgery editorial team (2026). utcardiothoracicsurgery.com (nicht-peer-reviewed)CLink - NAD und NMN in Nahrungsergänzungsmitteln?
Verbraucherzentrale Deutschland (2024). Verbraucherzentrale.deBLink - NMN in Deutschland: Rechtslage, EU Novel Food und Zugang (2026)
Longevity Germany Redaktion (2026). longevity-germany.comCLink - NMN Regulatory Status 2026: USA, EU & China
Provita Bio editorial team (2026). provitabio.comCLink - Sublingual NMN vs Oral: Bioavailability & Absorption 2026
NMN Labo editorial team (2026). nmnlabo.com (nicht-peer-reviewed)CLink - Welche Nebenwirkungen oder Nachteile hat NMN?
Xonigen Redaktion (2024). xonigen.com (nicht-peer-reviewed)CLink - Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials
Kuerec AH, Maier AB (2024). NutrientsAPMID:39203059DOI - The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Huang H (2023). Advances in NutritionBDOI - Nicotinamide mononucleotide (NMN)
Wikipedia contributors (2024). WikipediaCLink - The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications
Liao B, Zhao Y, Wang D, et al. (2024). Frontiers in PharmacologyBDOI - Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men
Irie J, Inagaki E, Fujita M, et al. (2020). Endocrine JournalAPMID:31685720DOI - Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Yoshino M, Yoshino J, Kayser BD, et al. (2021). ScienceAPMID:33888596DOI - Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials
Kuerec AH, Lin Y, Maier AB (2024). Journal of Nutrition, Health and Aging / PMCADOI - Nicotinamid-Mononukleotid (NMN) als Nahrungsergänzung für gesunde Erwachsene
Deutsches Gesundheitsportal (2025). Deutsches GesundheitsportalCLink
Community Sources
Storage
Unopened
Store in a cool, dry, light-protected location; room temperature up to max. 25°C.
Opened
Keep container tightly sealed; avoid moisture and heat.
Notes
NMN is thermolabile and can degrade to nicotinamide at elevated temperatures [s16]. Refrigerated storage is recommended for powder forms. Do not store in humid environments (bathroom, kitchen near steam).